The effect of intravitreal bevacizumab (Avastin) injection on retinal blood flow velocity in patients with choroidal neovascularization

European Journal of Ophthalmology

Volumn 22, Issue 3, 2012, Pages 423-430

  Barak, Adiel ^a   Burgansky Eliash, Zvia ^b   Barash, Hila ^c   Nelson, Darin A ^c   Grinvald, Amiram ^d   Loewenstein, Anat ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

^c Optical Imaging Ltd   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Bevacizumab; Blood flow; Flow velocity; Imaging; Retinal functional imager

Indexed keywords

BEVACIZUMAB;

ARTERY BLOOD FLOW; ARTICLE; BLOOD FLOW VELOCITY; CENTRAL MACULAR THICKNESS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ISRAEL; NON INVASIVE PROCEDURE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA BLOOD FLOW; RETINA MACULA LUTEA; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VEIN BLOOD FLOW; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD FLOW VELOCITY; BLOOD PRESSURE; CHOROIDAL NEOVASCULARIZATION; FEMALE; HEART RATE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; RETINA; RETINAL VESSELS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84863316257     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000074     Document Type: Article

References (50)

1. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Agerelated macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003; 48: 257-293.
2. Dorrell M, Uusitalo-Jarvinen H, Aguilar E, Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 2007; 52(suppl 1): S3-19.
3. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41: 614-625.
4. Pournaras CJ, Rungger-Brändle E, Riva CE, Hardarson SH, Stefansson E. Regulation of retinal blood flow in health and disease. Prog Retin Eye Res 2008; 27: 284-330.
5. Shams N, Ianchulev T. Role of vascular endothelial growth factor in ocular angiogenesis. Ophthalmol Clin North Am 2006; 19: 335-344.
6. Tong JP, Yao YF. Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. Clin Biochem 2006; 39: 267-276.
7. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
8. Zhang SX, Ma JX. Ocular neovascularization: implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007; 26: 1-37.
9. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium- derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res 2006; 82: 99-110.
10. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008; 27: 372-390.
11. van Wijngaarden P, Qureshi SH. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. Clin Exp Optom 2008; 91: 427-437.
12. Badalà F. The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008; 19: 234-238.
13. Ziemssen F, Zhu Q, Peters S, et al, Tübingen Bevacizumab Study Group. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009; 29: 213-224.
14. Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10: 3331-3348.
15. Saint-Geniez M, D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol 2004; 48: 1045-1058.
16. Saint-Geniez M, Maharaj ASR, Walshe TE, et al. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008; 3: e3554.
17. Grinvald A, Bonhoeffer T, Vanzetta I, et al. High-resolutionfunctional optical imaging: from the neocortex to the eye. Ophthalmol Clin North Am 2004; 17: 53-67.
18. Nelson DA, Krupsky S, Pollack A, et al. Special report: Noninvasive multi-parameter functional optical imaging of the eye. Ophthalmic Surg Lasers Imaging 2005; 36: 57-66.
19. Abràmoff MD, Kwon YH, Ts'o D, et al. Visual stimulus-induced changes in human near-infrared fundus reflectance. Invest Ophthalmol Vis Sci 2006; 47: 715-721.
20. Hanazono G, Tsunoda K, Shinoda K, Tsubota K, Miyake Y, Tanifuji M. Intrinsic signal imaging in macaque retina reveals different types of flash-induced light reflectance changes of different origins. Invest Ophthalmol Vis Sci 2007; 48: 2903-2912.
21. Grinvald A, Lieke E, Frostig RD, Gilbert CD, Wiesel TN. Functional architecture of cortex revealed by optical imaging of intrinsic signals. Nature 1986; 324: 361-364.
22. Landa G, Garcia PM, Rosen RB. Correlation between retina blood flow velocity assessed by retinal function imager and retina thickness estimated by scanning laser ophthalmoscopy/ optical coherence tomography. Ophthalmologica 2009; 223: 155-161.
23. Birger Y, Blumenfeld O, Bartov E, Burgansky-Eliash Z. Reduced retinal blood flow velocity in severe hyperlipidemia measured by the retinal function imager. Graefes Arch Clin Exp Ophthalmol 2011;249:1587-1590.
24. Beutelspacher SC, Serbecic N, Barash H, Burgansky-Eliash Z, Grinvald A, Jonas JB. Central serous chorioretinopathy shows reduced retinal flow circulation in retinal function imaging (RFI). Acta Ophthalmol 2011; 89: e479-482.
25. Burgansky-Eliash Z, Nelson DA, Bar-Tal OP, Lowenstein A, Grinvald A, Barak A. Reduced retinal blood flow velocity in diabetic retinopathy. Retina 2010; 30: 765-773.
26. Bonnin P, Pournaras JA, Lazrak Z, et al. Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin®) in neovascular age-related macular degeneration. Acta Ophthalmol 2010; 88: 641-645.
27. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009; 50: 1025-1032.
28. Papadopoulou DN, Mendrinos E, Mangioris G, Donati G, Pournaras CJ. Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular agerelated macular degeneration. Ophthalmology 2009; 116: 1755-61.
29. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20: 3804-3814.
30. Akella NS, Twieg DB, Mikkelsen T, et al. Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging 2004; 20: 913-922.
31. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endo-7. thelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323.
32. Zhu AX, Holalkere NS, Muzikansky A, Horgan K, Sahani DV. Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma. Oncologist 2008; 13: 120-125.
33. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147.
34. Grunwald JE, Metelitsina TI, Dupont JC, Ying GS, Maguire MG. Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005; 46: 1033-1038.
35. Metelitsina TI, Grunwald JE, DuPont JC, Ying GS, Brucker AJ, Dunaief JL. Foveolar choroidal circulation and choroidal neovascularization in age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 358-363.
36. Mori F, Konno S, Hikichi T, Yamaguchi Y, Ishiko S, Yoshida A. Pulsatile ocular blood flow study: decreases in exudative age related macular degeneration. Br J Ophthalmol 2001; 85: 531-533.
37. Sato E, Feke GT, Menke MN, Wallace McMeel J. Retinal haemodynamics in patients with age-related macular degeneration. Eye 2006; 20: 697-702.
38. Micieli JA, Tsui E, Lam W-C, Brent MH, Devenyi RG, Hudson C. Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration. Acta Ophthalmol Epub 2011 Jul 29.
39. Wickremasinghe SS, Guymer RH, Wong TY, Kawasaki R, Wong W, Qureshi S. Retinal venular caliber dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Clin Exp Ophthalmol Epub 2011 Jun 13.
40. Fontaine O, Olivier S, Descovich D, Cordahi G, Vaucher E, Lesk MR. The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration. Invest Ophthalmol Vis Sci 2011; 52: 7400-7405.
41. Toklu Y, Cakmak HB, Raza S, Anayol A, Asik E, Şimşek Ş. Short-term effects of intravitreal bevacizumab (Avastin®) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration. Acta Ophthalmol 2011; 89: e41-45.
42. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina 2007; 27: 432-438.
43. Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 2009; 29: 723-731.
44. Ritter M, Elledge J, Simader C, et al. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. Br J Ophthalmol 2011; 95: 381-385.
45. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 4300-4307.
46. Krebs I, Hagen S, Brannath W, et al. Repeatability and reproducibility of retinal thickness measurements by optical coherence tomography in age-related macular degeneration. Ophthalmology 2010; 117: 1577-1584.
47. Wolf-Schnurrbusch UEK, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009; 50: 3432-3437.
48. Forte R, Cennamo GL, Finelli ML, de Crecchio G. Comparison of time domain Stratus OCT and spectral domain SLO/ OCT for assessment of macular thickness and volume. Eye 2009; 23: 2071-2078.
49. Lammer J, Scholda C, Prünte C, Benesch T, Schmidt-Erfurth U, Bolz M. Retinal thickness and volume measurements in diabetic macular edema: a comparison of four optical coherence tomography systems. Retina 2011; 31: 48-55.
50. Leung CK, Cheung CY, Weinreb RN, et al. Comparison of macular thickness measurements between time domain and spectral domain optical coherence tomography. Invest Ophthalmol Vis Sci 2008; 49: 4893-4897.